27313723|t|Significance of ETV6 rearrangement in acute promyelocytic leukemia with t(15;17)/ promyelocytic leukemia / retinoic acid receptor alpha
27313723|a|Acute promyelocytic leukemia (APL) is a common subtype of acute myeloid leukemia in China. Since the application of arsenic trioxide and all-trans retinoic acid in the treatment of APL, the prognosis has greatly improved. However, ~20% of patients with APL relapse upon completing chemotherapy. Decreasing the relapse rate and incidence of early mortality may pose the greatest challenges for the future management of APL. Recently, Ets variant 6 (ETV6) was reported to be involved in a variety of translocations associated with hematological malignancies of myeloid and lymphoid origin. To date, little is known about the clinical implication of ETV6 rearrangement in APL. In the present study, ETV6 rearrangement was examined by split-signal fluorescence in situ hybridization in 258 adults with APL, and its association with the clinical features and outcomes of the patients was analyzed. The data suggested that ETV6 rearrangement may be an independent unfavorable prognostic factor for overall survival in APL patients.
27313723	16	20	ETV6	T017	UMLS:C0796520
27313723	21	34	rearrangement	T038	UMLS:C0017287
27313723	38	66	acute promyelocytic leukemia	T038	UMLS:C0023487
27313723	82	104	promyelocytic leukemia	T038	UMLS:C2745900
27313723	107	135	retinoic acid receptor alpha	T103	UMLS:C0140279
27313723	136	164	Acute promyelocytic leukemia	T038	UMLS:C0023487
27313723	166	169	APL	T038	UMLS:C0023487
27313723	183	190	subtype	T170	UMLS:C0449560
27313723	194	216	acute myeloid leukemia	T038	UMLS:C0023467
27313723	220	225	China	T082	UMLS:C0008115
27313723	252	268	arsenic trioxide	T103	UMLS:C0052416
27313723	273	296	all-trans retinoic acid	T103	UMLS:C0040845
27313723	317	320	APL	T038	UMLS:C0023487
27313723	326	335	prognosis	T058	UMLS:C0033325
27313723	389	392	APL	T038	UMLS:C0023487
27313723	417	429	chemotherapy	T058	UMLS:C3665472
27313723	476	491	early mortality	T033	UMLS:C1836407
27313723	514	524	challenges	T058	UMLS:C0805586
27313723	540	550	management	T058	UMLS:C0376636
27313723	554	557	APL	T038	UMLS:C0023487
27313723	569	582	Ets variant 6	T017	UMLS:C0796520
27313723	584	588	ETV6	T017	UMLS:C0796520
27313723	594	602	reported	T058	UMLS:C0700287
27313723	634	648	translocations	T038	UMLS:C1315049
27313723	665	691	hematological malignancies	T038	UMLS:C0376545
27313723	783	787	ETV6	T017	UMLS:C0796520
27313723	788	801	rearrangement	T038	UMLS:C0017287
27313723	805	808	APL	T038	UMLS:C0023487
27313723	825	830	study	T062	UMLS:C0008972
27313723	832	836	ETV6	T017	UMLS:C0796520
27313723	837	850	rearrangement	T038	UMLS:C0017287
27313723	867	914	split-signal fluorescence in situ hybridization	T062	UMLS:C0162789
27313723	934	937	APL	T038	UMLS:C0023487
27313723	1019	1027	analyzed	T062	UMLS:C0936012
27313723	1053	1057	ETV6	T017	UMLS:C0796520
27313723	1058	1071	rearrangement	T038	UMLS:C0017287
27313723	1106	1123	prognostic factor	T201	UMLS:C1514474
27313723	1148	1151	APL	T038	UMLS:C0023487